Prevalence of yersinia plasmid-encoded outer protein (Yop) class-specific antibodies in multitransfused Greek patients with thalassemic syndromes

Clinical Microbiology and Infection

Volumn 5, Issue 2, 1999, Pages 67-72

  Chatzipanagiotou, S ^a,b   Ladis, V ^c   Berdousi, H ^c   Palamidou, F ^c   Kourti, E ^a   Kattamis, C ^c   Legakis, Nicholas J ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b 1st IKA Hospital   (Greece)

^c AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

Antibodies; Thalassemia; Yersinia enterocolitica; Yersinia outer proteins (Yops)

Indexed keywords

ANTIBODY; ANTIGEN; BACTERIAL PROTEIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY;

ADOLESCENT; ADULT; AGGLUTINATION TEST; ARTICLE; BACTERIAL INFECTION; BETA THALASSEMIA; BLOOD CULTURE; BLOOD DONOR; BLOOD TRANSFUSION; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; PLASMID; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; SEROPREVALENCE; SEROTYPE; YERSINIA; YERSINIA ENTEROCOLITICA; YERSINIA PESTIS; YERSINIA PSEUDOTUBERCULOSIS;

BACTERIA (MICROORGANISMS); YERSINIA; YERSINIA ENTEROCOLITICA; YERSINIA PESTIS; YERSINIA PSEUDOTUBERCULOSIS;

EID: 0033022512     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1999.tb00105.x     Document Type: Article

References (51)

1. Cover TL, Aber RC. Yersinia enterocolitica. N Engl J Med 1989; 321: 16-24.
2. Hoogkamp-Korstanje J, de Koning J, Heesemann J. Persistence of Yersinia enterocolitica in man. Infection 1988; 16: 81-5.
3. Knapp W, Thal E. Differentiation of Yersinia enterocolitica by biochemical reactions. Contrib Microbiol Immunol 1973; 2: 10-16.
4. Bienner DJ, Steigerwalt AG, Falcão DP, Weaver RB, Fanning GR. Characterization of Yersinia enterocolitica and Yersinia pseudotuberculosis by deoxyribonucleic acid hybridization and by biochemical reactions. Int J Syst Bacteriol 1976; 26: 180-94.
5. Cornelis G, Laroche Y, Balligand G, Sory M, Wauters G. Yersinia enterocolitica, a primary model for bacterial invasiveness. Rev Infect Dis 1987; 9: 64-87.
6. Cornelis G, Biot T, Lambert de Ronvroit C, et al. The Yersinia Yop regulon. Mol Microbiol 1989; 3: 1455-9.
7. Cornelis G, Sluiters C, Delors I, et al. YmoA, a Yersinia enterocolitica chromosomal gene modulating the expression of virulence functions. Mol Microbiol 1991; 5: 1023-4.
8. Delor I, Cornelis G. Role of Yersinia enterocolitica Yst toxin in experimental infection of young rabbits. Infect Immun 1992; 60: 4269-77.
9. Bäumler A, Koebnik R, Stojilkovic I, Heesemann J, Braun V, Hantke K. Survey on newly characterized iron uptake systems of Yersinia enterocolitica. Zentralbl Bakteriol 1993; 278: 416-24.
10. Modell B. Advances in the use of iron-chelating agents for the treatment of iron overload. Prog Hematol 1979; 11: 267-312.
11. Hoen B, Renoult E, Jonon B, Kessler M. Septicemia due to Yersinia enterocolitica in a long term hemodialysis patient after a single desferrioxamine administration. Nephron 1988; 50: 378-9.
12. Krüger N, Kraus C, Tillmann W, Schröter W. Gehäuftes Auftreten von Yersiniensepsis bei Hämosiderose. Monatschr Kinderheilkd 1985; 133: 876-8.
13. Melby K, Slordahl S, Gutteberg TJ, Nordbo SA. Septicemia due to Yersinia enterocolitica after oral overdoses of iron. Br Med J Clin Res 1982; 285: 467-8.
14. Seifert A, von Herrath D, Schaefer K. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. Q J Med 1987; 65: 1015-24.
15. Robins-Browne RM, Prpic JK. Desferrioxamine and systemic yersiniosis. Lancet 1983; 2: 1372.
16. Robins-Browne RM, Prpic JK. Effects of iron and desterrioxamine on infections with Yersinia enterocolitica. Infect Immun 1985; 47: 774-9.
17. Butzler J, Alexander M, Segers A, Cremer N, Wauters G. Enteritis abscess and septicemia by Yersinia enterocolitica in a thalassemic child. Contrib Microbiol Immunol 1979; 5: 292.
18. Kattamis C, Ladis V, Vekiou-Samara A. Yersinia enterocolitica in patients with β-thalassemia. In Sirchia G, Zanella A, eds. Thalassemia today. The Mediterannean Experience. Milano, 1987: 591-6.
19. Hoogkamp-Korstanje JAA. Yersiniosis in childhood: incidence and diagnosis. In Simon C, Wilkinson P, eds. Diagnosis of infectious diseases: new aspects. Stuttgart: Schattauer, 1986: 67-9.
20. Bottone EJ, Sheehan DJ. Yersinia enterocolitica: guidelines for serologic diagnosis of human infections. Rev Infect Dis 1983; 5: 898-906.
21. Cover TL, Aber RC. Yersinia enterocolitica. N Engl J Med 1989; 321: 16-24.
22. Heesemann J, Eggers C, Schröder J. Serological diagnosis of yersiniosis by immunoblot technique using virulence-associated antigen of enteropathogenic yersiniae. Contrib Microbiol Immunol 1987; 9: 285-9.
23. Heesemann J, Gross U, Schmidt N, Laufs R. Immunochemical analysis of plasmid-encoded proteins released by enteropathogenic Yersinia sp. grown in calcium-deficient media. Infect Immun 1986; 54: 561-7.
24. Schoerner C, Wartenberg K, Röllinghoff M. Differentiation of serological responses to Yersinia enterocolitica serotype O9 and Brucella species by immunoblot or enzyme-linked immunosorbent assay using whole bacteria and yersinia outer membrane proteins. J Clin Microbiol 1990; 28: 1570-4.
25. Autenrieth IB, Hantke K, Heesemann J. Immunosuppression of the host and delivery of iron to the pathogen: a possible dual role of siderophores in the pathogenesis of microbial infections? Med Microbiol Immunol 1991; 180: 135-41.
26. Autenrieth IB, Reissbrodt R, Saken E, et al. Desferrioxamine-promoted virulence of Yersinia enterocolitica for mice depends on both desferrioxamine type and mouse strain. J Infect Dis 1994; 169: 562-7.
27. Bottomley SS, Wolfe LC, Bridges KR. Iron metabolism in K562 erythroleukemic cells. J Biol Chem 1985; 260: 6811-15.
28. Laub R, Schneider YJ, Octave JN, Trovet A, Crichton RR. Cellular pharmacology of desferrioxamine B derivatives in cultured rat hepatocytes in relation to iron mobilization. Biochem Pharmacol 1985; 34: 1175-83.
29. Kontoghiorghes GJ, Sheppard L, Hoffbrand AV, Charalambous J, Tikerpae J, Pippard MJ. Iron chelation studies using desferrioxamine and the potential oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats. J Clin Pathol 1987; 40: 404-8.
30. Carotenuto P, Pontesilli O, Cambier JC, Hayward AR. Desferrioxamine blocks IL 2 receptor expression on human T lymphocytes. J Immunol 1986; 136: 2342-7.
31. Sia DY. Immuno-modulation of human T lymphocyte function by desferrioxamine (Desferal). Immunopharmacology 1987; 14: 135-43.
32. Ledermann HM, Cohen A, Lee JW, Freedman MH, Gelfand EW. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood 1984; 64: 748-53.
33. Cantineaux B, Hariga C, Ferster A, De Maertelaere E, Toppet M, Fondu P. Neutrophil dysfunctions in thalassemia major: the role of cell iron overload. Eur J Haematol 1987; 39: 28-34.
34. Cantinieaux B, Boelaert J, Hariga C, Fondu P. Impaired neutrophil defense against Yersinia enterocolitica in patients with iron overload who are undergoing dialysis. J Lab Clin Med 1988; 111: 524-8.
35. Lima MF, Kierszenbaum F. Lactoferrin effects of phagocytic cell function. II. The presence of iron is required for the lactoferrin molecule to stimulate intracellular killing by macrophages but not to enhance the uptake of particles and microorganisms. J Immunol 1987; 139: 1647-51.
36. Haber F, Weiss J. The catalytic decomposition of hydrogen peroxide by iron salts. Proc R Soc Lond A 1934; 147: 332-51.
37. Waterlot Y, Cantinieaux B, Hariga Muller C, De Maertelaere Laurent E, Vanherweghem JL, Fondu P. Impaired phagocytic activity of neutrophils in patients receiving haemodialysis: the critical role of iron overload. Br Med J (Clin Res Ed) 1985; 291: 501-4.
38. Cantinieaux B, Hariga C, Ferster A, Toppet M, Fondu P. Desferrioxamine improves neutrophil phagocytosis in thalassemia major. Am J Hematol 1990; 35: 13-17.
39. van Asbeck BS, Marx JJ, Struyvenberg A, van Kats JH, Verhoef J. Deferoxamine enhances phagocytic function of human polymorphonuclear leucocytes. Blood 1984; 63: 714-20.
40. Brock JH, Ng J. The effect of desferrioxamine on the growth of Staphylococcus aureus, Yersinia enterocolitica, and Streptococcus faecalis in human serum: uptake of desferrioxamine-bound iron. FEMS Microbiol Lett 1983; 20: 439-42.
41. Lian CJ, Pai CH. Inhibition of human neutrophil chemiluminescence by plasmid-mediated outer membrane proteins of Yersinia enterocolitica. Infect Immun 1985; 49: 145-51.
42. Guan K, Dixon J. Protein tyrosine phosphatase activity of an essential virulence determinant in Yersinia. Science 1990; 249: 553-6.
43. Rosqvist R, Bolin I, Wolf Watz H. Inhibition of phagocytosis in Yersinia pseudotuberculosis: a virulence plasmid-encoded ability involving the Yop 2b protein. Infect Immun 1988; 56: 2139-43.
44. Heesemann J. Enteropathogene Yersinien: Pathogenitätsfaktoren und neue diagnostische Methoden. Immun Infekt 1990; 18: 186-91.
45. Hoogkamp-Korstanje JAA, de Koning J, Samson JP. Incidence of human infection with Yersinia enterocolitica serotypes O3, O8 and O9 and the use of indirect immnunofluorescence in diagnosis. J Infect Dis 1986; 153: 139-41.
46. Hoogkamp-Korstanje JAA, de Koning J. Yersinia enterocolitica ifecties; klinische histologie en histologische kenmerken, diagnostiek en therapie. Ned Tijdschr Geneeskd 1991; 135: 2218-23.
47. Heesemann J, Algermissen B, Laufs R, Genetically manipulated virulence of Yersinia enterocolitica. Infect Immun 1984; 46: 105-10.
48. Hoogkamp-Korstanje JAA, de Koning J, Heesemann J. Persistence of Yersinia enterocolitica in man. Infection 1988; 6: 81-5.
49. Vogel U, Autenrieth IB, Berner R, Heesemann J. Role of plasmid-encoded antigens of Yersinia enterocolitica in humoral immunity against secondary Y. enterocolitica infection in mice. Microb Pathogen 1993; 15: 23-36.
50. Butzler JP, Alexander M, Segers A, et al. Enteritis abscess and septicemia due to Yersinia enterocolitica in a child with thalassemia. J Pediatr 1978; 93: 619-21.
51. Scharnetzky M, König R, Lakomek M, et al. Prophylaxis of systemic yersiniosis in thalassemia major. Lancet 1984; 1: 71.